Brian Lian, Viking Therapeutics CEO
June 4, 2024 10:57 AM EDT
R&D

Viking ex­pands on Phase 2b da­ta for NASH drug, tout­ing his­to­log­i­cal end­points

Max Gelman

Senior Editor

Viking Ther­a­peu­tics an­nounced Tues­day morn­ing new da­ta from a Phase 2b tri­al look­ing at its NASH drug, aim­ing to pro­vide a fuller pic­ture of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Ab­b­Vie pens an­oth­er T cell en­gager deal, this time with Xilio

Bio­gen gets $250M in Roy­al­ty Phar­ma deal for Phase 3 lu­pus pro­gram

Bio­gen down­plays ca­pac­i­ty for M&A; Roche’s SMA drug is ap­proved as a tablet

Anap­tys­Bio gets a mid-stage win for PD-1 drug in rheuma­toid arthri­tis

Ex­clu­sive: Longevi­ty start­up tar­gets rene­gade pro­teins linked to di­a­betes and obe­si­ty

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times